Horizon Discovery

Despite recent advances, the pharmaceutical industry is still pursuing expensive, and lengthy, approaches to the discovery of oncology drugs with limited efficacy and safety. This results in treatments which are unpleasant for the patient and susceptible to a reduction in effectiveness (resistance). Using innovative genetic manupulation tools, Horizon Discovery has access to a new technology which will allow itself, and partner pharmaceutical companies, to develop cost-effective medicines that are optimally tailored to specific cancer defects. By taking such a focused, 'personalised medicine', approach, Horizon Discovery will be able to reduce drug development costs and supply better medicines to the patient.


Members: 
Adam Collier
Members: 
Christopher Torrance
Members: 
Robert Howes
Website: 

none